We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

Phil Nadeau, an analyst from TD Cowen, maintained the Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

In its upcoming report, Vertex Pharmaceuticals (VRTX ... trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings ...

This partnership will bring together the multimodality and natural language capabilities of Gemini on Vertex AI – Google ...

Vertex Pharmaceuticals Inc. (VRTX) released a profit for its third quarter that increased from the same period last year and beat ...

Earnings per Share (EPS): Vertex's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.03. Debt Management: With a high debt-to-equity ratio ...

With an FDA decision looming over its first foray into the acute pain space, Vertex Pharmaceuticals has commissioned a pair of surveys to take stock of that space. The resulting report ...

“With this key asset shift safely executed, our focus continues on further optimization of the business in pursuit of sustained performance and longer-term growth.” Vertex said the conversion ...